All Phenotypes Tg(MUC1)79.24Gend MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Tg(MUC1)79.24Gend
transgene insertion 79.24, Sandra J Gendler
MGI:3777621

Summary

5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Kras^tm4Tyj/Kras⁺ Ptf1a^{tm1.1(cre)Cvw}/Ptf1a⁺ Tg(MUC1)79.24Gend/0	B6.Cg-Kras^tm4Tyj Ptf1a^{tm1.1(cre)Cvw} Tg(MUC1)79.24Gend	MGI:3836556
cn2	Kras^tm4Tyj/Kras⁺ Tg(MUC1)79.24Gend/0	involves: 129S4/SvJae * C57BL/6	MGI:4411919
cx3	Il10^tm1Cgn/Il10^tm1Cgn Tg(MUC1)79.24Gend/0	B6.Cg-Il10^tm1Cgn Tg(MUC1)79.24Gend	MGI:5432215
cx4	Tg(Ela1-TAg*)79Mjt/0 Tg(MUC1)79.24Gend/0	involves: C57BL/6 * DBA/2	MGI:3777635
tg5	Tg(MUC1)79.24Gend/0	involves: C57BL/6	MGI:3777623

Allelic Composition	Kras^tm4Tyj/Kras⁺ Ptf1a^{tm1.1(cre)Cvw}/Ptf1a⁺ Tg(MUC1)79.24Gend/0
Genetic Background	B6.Cg-Kras^tm4Tyj Ptf1a^{tm1.1(cre)Cvw} Tg(MUC1)79.24Gend

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kras^tm4Tyj mutation (9 available); any Kras mutation (84 available)
Ptf1a^{tm1.1(cre)Cvw} mutation (1 available); any Ptf1a mutation (31 available)
Tg(MUC1)79.24Gend mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:138959 , J:234412 )

• pancreatic tumors exhibit lower proliferation rates than in Kras^tm4Tyj Ptf1a^{tm1.1(cre)Cvw} Tg(MUC1)79.24Gend heterozygotes (J:138959)

• mice exhibit carcinoma in situ in the pancreas (J:234412)

increased pancreatic ductal adenocarcinoma incidence ( J:138959 )

• in 1 of 10 mice at 26 weeks

increased pancreatic intraepithelial neoplasia incidence ( J:138959 , J:234412 )

• mice exhibit high-grade PanIN lesions and carcinoma in situ, associated with disorganized glandular epithelium (J:234412)

• mice treated with gemcitabine exhibit normal pancreatic glandular structure 26 weeks after the beginning of treatment (J:234412)

decreased metastatic potential ( J:138959 )

• at 48 weeks, 6 of 10 mice develop metastasis to the lung and liver compared to 4 of 10 metastasis at 34 weeks of age in Kras^tm4Tyj Ptf1a^{tm1.1(cre)Cvw} Tg(MUC1)79.24Gend heterozygotes

endocrine/exocrine glands

increased pancreas tumor incidence ( J:138959 , J:234412 )

• pancreatic tumors exhibit lower proliferation rates than in Kras^tm4Tyj Ptf1a^{tm1.1(cre)Cvw} Tg(MUC1)79.24Gend heterozygotes (J:138959)

• mice exhibit carcinoma in situ in the pancreas (J:234412)

increased pancreatic ductal adenocarcinoma incidence ( J:138959 )

• in 1 of 10 mice at 26 weeks

increased pancreatic intraepithelial neoplasia incidence ( J:138959 , J:234412 )

• mice exhibit high-grade PanIN lesions and carcinoma in situ, associated with disorganized glandular epithelium (J:234412)

• mice treated with gemcitabine exhibit normal pancreatic glandular structure 26 weeks after the beginning of treatment (J:234412)

Mouse Models of Human Disease	DO ID	OMIM ID(s)	Ref(s)
adenoma	DOID:657		J:138959
pancreatic carcinoma	DOID:4905	OMIM:260350	J:234412

Allelic Composition	Kras^tm4Tyj/Kras⁺ Tg(MUC1)79.24Gend/0
Genetic Background	involves: 129S4/SvJae * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kras^tm4Tyj mutation (9 available); any Kras mutation (84 available)
Tg(MUC1)79.24Gend mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

uterus adenomyosis ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, all mice develop ovarian lesions consisting of endometrial glandular epithelium unlike un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice

immune system

increased regulatory T cell number ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice with endometriosis also exhibit an increase in spleen and regional lymph nodes T regulatory cells compared with un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice

increased IgG level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice

increased IgM level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in MUC1-specific IgM unlike un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice and similarly treated Tg(MUC1)79.24Gend mice

decreased interferon-gamma secretion ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, T cells in the spleen and regional lymph nodes exhibit decreased IFN-gamma in response to polyclonal stimulation compared with un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice

hematopoietic system

increased regulatory T cell number ( J:154046 )

increased IgG level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Kras^tm4Tyj Tg(MUC1)79.24Gend mice

increased IgM level ( J:154046 )

Allelic Composition	Il10^tm1Cgn/Il10^tm1Cgn Tg(MUC1)79.24Gend/0
Genetic Background	B6.Cg-Il10^tm1Cgn Tg(MUC1)79.24Gend

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Il10^tm1Cgn mutation (15 available); any Il10 mutation (45 available)
Tg(MUC1)79.24Gend mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

digestive/alimentary system

rectal prolapse ( J:149347 )

• rectal prolapse is seen at a median time of 11 weeks of age

increased colon adenocarcinoma incidence ( J:149347 )

• 88% of mutants with colonic inflammation exhibit colon tumors; majority of tumors are invasive adenocarcinomas

• mutants exhibit a higher tumor burden (3-4 tumors per colon on average) than single Il10 homozygotes (1 tumor per colon)

• tumors develop as early as 8-12 weeks of age

large intestinal inflammation ( J:149347 )

• mutants develop segmental, patchy colon inflammation with areas of healthy-appearing colon adjacent to areas of severe inflammation

• mutants exhibit higher total colonic inflammation at 5-6 weeks of age than single Il10 homozygotes and show fewer fields of no inflammation

• neutrophils are the dominant cellular infiltrate in the colon which are not seen in the single Il10 homozygote

• mutants develop progressive inflammatory bowel disease much earlier than single Il10 homozygotes

immune system

large intestinal inflammation ( J:149347 )

• mutants develop segmental, patchy colon inflammation with areas of healthy-appearing colon adjacent to areas of severe inflammation

• mutants exhibit higher total colonic inflammation at 5-6 weeks of age than single Il10 homozygotes and show fewer fields of no inflammation

• neutrophils are the dominant cellular infiltrate in the colon which are not seen in the single Il10 homozygote

• mutants develop progressive inflammatory bowel disease much earlier than single Il10 homozygotes

neoplasm

increased colon adenocarcinoma incidence ( J:149347 )

• 88% of mutants with colonic inflammation exhibit colon tumors; majority of tumors are invasive adenocarcinomas

• mutants exhibit a higher tumor burden (3-4 tumors per colon on average) than single Il10 homozygotes (1 tumor per colon)

• tumors develop as early as 8-12 weeks of age

Mouse Models of Human Disease	DO ID	OMIM ID(s)	Ref(s)
colorectal cancer	DOID:9256	OMIM:114500	J:149347
inflammatory bowel disease	DOID:0050589	OMIM:PS266600	J:149347

Allelic Composition	Tg(Ela1-TAg*)79Mjt/0 Tg(MUC1)79.24Gend/0
Genetic Background	involves: C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Ela1-TAg*)79Mjt mutation (0 available)
Tg(MUC1)79.24Gend mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:64570 )

• mice develop pancreatic tumors that can be grossly visualized at 9 weeks of age

• at 18 and 21 weeks, mice develop large solid tumor masses of less differentiated acinar cell carcinomas

increased pancreas adenoma incidence ( J:64570 )

• pancreas consists of acinar cell microadenomas

increased pancreatic acinar cell carcinoma incidence ( J:64570 )

• pancreas consists of acinar cell carcinomas; well-differentiated acinar cell carcinomas are observed

endocrine/exocrine glands

abnormal pancreas morphology ( J:64570 )

• double transgenic mice exhibit acinar cell dysplasia at birth, which progresses to single or multiple cell acinar cell carcinomas

• increased pancreas weight is general indicator of tumor burden, but in many animals 15 weeks of age or older, pancreas weights do not increase presumably due to cachexia

increased pancreas tumor incidence ( J:64570 )

• mice develop pancreatic tumors that can be grossly visualized at 9 weeks of age

• at 18 and 21 weeks, mice develop large solid tumor masses of less differentiated acinar cell carcinomas

increased pancreas adenoma incidence ( J:64570 )

• pancreas consists of acinar cell microadenomas

increased pancreatic acinar cell carcinoma incidence ( J:64570 )

• pancreas consists of acinar cell carcinomas; well-differentiated acinar cell carcinomas are observed

immune system

immune system phenotype ( J:64570 )

N	• nonimmunized mice develop anti-MUC1 cytotoxic T lymphocytes by 12 weeks and show 80% lysis of MUC1-expressing target cells by 18 weeks

Allelic Composition	Tg(MUC1)79.24Gend/0
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(MUC1)79.24Gend mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

abnormal humoral immune response ( J:128899 )

• mice challenged with MUC1-expressing tumor cells do not develop IgM or IgG3 responses, and only 1 transgenic mouse showed an IgG1 antibody response, whereas most wild-type mice similarly challenged showed strong MUC1-specific IgM, IgG1, and half showed strong IgG3 responses

• in response to immunization with 5.25 copies of the MUC1 tandem repeat, wild-type mice generate strong responses in the IgM and all IgG isotypes, but transgenic mice show a strong IgM response but only weak IgG subtype responses

increased IgG level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Tg(MUC1)79.24Gend mice

increased IgM level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in MUC1-specific IgM unlike un-injected Tg(MUC1)79.24Gend mice

neoplasm

increased tumor incidence ( J:128899 )

• after injection of B16.9 melanoma cells, transgenic mice develop progressively growing tumors (average tumor volume 1.31 cm²) at day 26 postinjection

• tumor growth is significantly accelerated compared to injected wild-type mice where only 1 mouse had a tumor at 26 days postinjection; majority of wild-type mice have tumors at 34 days with an average volume of 0.11 cmL²

hematopoietic system

increased IgG level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Tg(MUC1)79.24Gend mice

increased IgM level ( J:154046 )

• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in MUC1-specific IgM unlike un-injected Tg(MUC1)79.24Gend mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24